{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=16", "query": { "intervention": "gemcitabine", "page": 16 }, "page_size": 10 }, "pagination": { "page": 16, "page_size": 10, "total_count": 1628, "total_pages": 163, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=17&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=gemcitabine&page=15&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T16:04:56.432Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04799249", "title": "Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving Gemcitabine and Carboplatin for Metastatic Triple-Negative Breast Cancer (TNBC)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "TNBC - Triple-Negative Breast Cancer", "Breast Cancer" ], "interventions": [ { "name": "Trilaciclib", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "G1 Therapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 194, "start_date": "2021-05-14", "completion_date": "2024-05-24", "has_results": false, "last_update_posted_date": "2024-08-01", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 16, "location_summary": "Gilbert, Arizona • Washington D.C., District of Columbia • St. Petersburg, Florida + 13 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Tampa", "state": "Florida" }, { "city": "Clinton", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04799249" }, { "nct_id": "NCT00336648", "title": "Preop Chemoradiation Resectable Pancreas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Neoplasms" ], "interventions": [ { "name": "Avastin (Bevacizumab)", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 11, "start_date": "2006-06", "completion_date": "2008-07", "has_results": false, "last_update_posted_date": "2012-07-30", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00336648" }, { "nct_id": "NCT00418093", "title": "Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 19, "start_date": "2006-09", "completion_date": "2011-10", "has_results": true, "last_update_posted_date": "2014-06-19", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00418093" }, { "nct_id": "NCT01325558", "title": "A Study of ALT-836 in Combination With Gemcitabine for Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Locally Advanced Malignant Neoplasm", "Malignant Solid Tumour" ], "interventions": [ { "name": "ALT-836 in combination with gemcitabine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Altor BioScience", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2011-05", "completion_date": "2015-02", "has_results": false, "last_update_posted_date": "2016-07-15", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 4, "location_summary": "Atlanta, Georgia • Iowa City, Iowa • Rochester, New York + 1 more", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Rochester", "state": "New York" }, { "city": "Charlotte", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT01325558" }, { "nct_id": "NCT06586515", "title": "MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Ductal Adenocarcinoma", "Non-small Cell Lung Cancer", "Colorectal Cancer" ], "interventions": [ { "name": "LY3962673", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "nab-paclitaxel", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "leucovorin", "type": "DRUG" }, { "name": "Irinotecan", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 630, "start_date": "2024-09-12", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-10-20", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 25, "location_summary": "Duarte, California • Santa Monica, California • Denver, Colorado + 18 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Santa Monica", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06586515" }, { "nct_id": "NCT01905150", "title": "Ph 2 Trial of Vitamin C & G-FLIP (Low Doses Gemcitabine, 5FU, Leucovorin, Irinotecan, Oxaliplatin) for Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "G-FLIP", "type": "DRUG" }, { "name": "G-FLIP-DM", "type": "DRUG" }, { "name": "Vitamin C", "type": "DIETARY_SUPPLEMENT" } ], "intervention_types": [ "DRUG", "DIETARY_SUPPLEMENT" ], "sponsor": "Bruckner Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 34, "start_date": "2014-08-13", "completion_date": "2020-01", "has_results": true, "last_update_posted_date": "2024-12-11", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 1, "location_summary": "The Bronx, New York", "locations": [ { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01905150" }, { "nct_id": "NCT02050178", "title": "Dose Escalation Study of OMP-54F28 in Combination With Nab-Paclitaxel and Gemcitabine in Patients With Previously Untreated Stage IV Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pancreatic Cancer", "Stage IV Pancreatic Cancer" ], "interventions": [ { "name": "OMP-54F28, Nab-Paclitaxel and Gemcitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "OncoMed Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 26, "start_date": "2013-11", "completion_date": "2017-06-15", "has_results": false, "last_update_posted_date": "2020-09-09", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 5, "location_summary": "Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Indianapolis", "state": "Indiana" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT02050178" }, { "nct_id": "NCT00033735", "title": "Irofulven Compared With Fluorouracil in Treating Patients With Pancreatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Pancreatic Cancer" ], "interventions": [ { "name": "fluorouracil", "type": "DRUG" }, { "name": "Irofulven", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 158, "start_date": "2000-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2012-12-24", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 1, "location_summary": "Bloomington, Minnesota", "locations": [ { "city": "Bloomington", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00033735" }, { "nct_id": "NCT02393248", "title": "Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lung Cancer", "Solid Tumor", "Gastric Cancer", "Urothelial Cancer", "Endometrial Cancer", "Multiple Myeloma", "Myeloproliferative Neoplasms", "Breast Cancer", "Cholangiocarcinoma", "UC", "MPN" ], "interventions": [ { "name": "Pemigatinib", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Trastuzumab", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 201, "start_date": "2015-02-27", "completion_date": "2021-12-17", "has_results": true, "last_update_posted_date": "2023-01-06", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 19, "location_summary": "Birmingham, Alabama • West Hollywood, California • New Haven, Connecticut + 16 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "West Hollywood", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02393248" }, { "nct_id": "NCT01606748", "title": "A Drug-Interaction Study of Necitumumab (IMC-11F8) in Combination With Gemcitabine-Cisplatin", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Malignant Solid Tumor" ], "interventions": [ { "name": "Necitumumab", "type": "BIOLOGICAL" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Eli Lilly and Company", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 35, "start_date": "2012-08", "completion_date": "2016-06", "has_results": true, "last_update_posted_date": "2019-09-30", "last_synced_at": "2026-10-24T16:04:56.432Z", "location_count": 4, "location_summary": "Scottsdale, Arizona • Detroit, Michigan • Las Vegas, Nevada + 1 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01606748" } ] }